معرفی
Dr. Ehab L. Atallah is a Professor of Medicine in the Department of Hematology and Oncology at the Medical College of Wisconsin, where he has been on faculty since 2007. He currently serves as Associate Director of the Cancer Service Line at Froedtert Hospital and previously held leadership positions as Section Head of Hematological Malignancies and Hematological Malignancies Disease-Oriented Team Lead. Dr. Atallah is a member of both the Cancer Center and Center for Immunology at MCW, with clinical expertise in hematologic malignancies.
Dr. Atallah's research focuses on hematologic malignancies with particular emphasis on chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). His work encompasses treatment-free remission strategies in CML, optimizing tyrosine kinase inhibitor therapy, studying TP53-mutated myeloid neoplasms, and developing novel treatment approaches for AML. He frequently investigates real-world treatment patterns and outcomes, with a strong interest in translating research findings into clinical practice. His recent publications demonstrate expertise in both clinical trials and observational studies, with significant contributions to national consortia including the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Analysis of Dr. Atallah's recent publications (2023-2025) reveals a strong focus on precision medicine approaches in hematologic malignancies, with particular attention to molecularly defined subgroups such as TP53-mutated diseases. His work spans multiple therapeutic areas including novel agent development (asciminib), combination therapies (venetoclax-based regimens), and treatment discontinuation strategies. The publications demonstrate a balance between mechanistic investigations and real-world evidence studies, reflecting his commitment to both scientific advancement and practical clinical application.
- Mentor Award (2017)
- Faculty Development Award (2016)
- Outstanding Medical Student Teacher Award (2014, 2016, 2021)
- Best Doctors in America (2015-2023)
- Department of Medicine Engstrom Murphy Award for Clinical Contribution (2015)
- Teacher of the Year Award by Internal Medicine residents (2009)
- MERIT award, ASCO Cancer Foundation (2007)
Dr. Atallah has served as Principal Investigator or Institutional PI for numerous research grants, including the ongoing ASC2ESCALATE trial (Phase II study of Asciminib in second-line CML), ECOG/ACRIN trials for AML and ALL, and a CTSI Traditional Pilot Award investigating RAS pathway activation in AML. He has mentored numerous fellows, residents, and medical students throughout his career, evidenced by multiple teaching awards. His leadership extends to national consortia where he serves as Steering Committee Chair for ASC2ESCALATE, Co-Chair of ECOG-ACRIN Leukemia, and member of the iCMLf Scientific Advisory Board.
As Associate Director of the Cancer Service Line at Froedtert Hospital, Dr. Atallah contributes to strategic planning and operational leadership for cancer care delivery. His research program benefits from strong institutional support at the Medical College of Wisconsin Cancer Center, where he has served on multiple committees including the Data Safety Monitoring Committee and Clinical Translational Pilot Grant Committee. His work often involves multi-institutional collaborations through national networks such as ECOG-ACRIN and the Consortium on Myeloid Malignancies and Neoplastic Diseases.
